Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Thiogenesis Therapeutics Corp V.TTI

Alternate Symbol(s):  TTIPF

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:TTI)

Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates

Newsfile 8 days ago

Thiogenesis Announces Important Core Patent Allowed in Europe

Newsfile November 4, 2024

Thiogenesis Announces Investor Relations Engagement

Newsfile September 27, 2024

Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium

Newsfile September 17, 2024

Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program

Newsfile August 20, 2024

Thiogenesis Announces Leigh Syndrome Clinical Program

Newsfile July 18, 2024

Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS

Newsfile March 25, 2024

Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement

Newsfile December 20, 2023

Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation

Newsfile December 18, 2023
View More News ››

Opinion & Analysis (TSXV:TTI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:TTI)

TTI Attains DTC Eligibility in the US

Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating...
MarketMakerss - 4 days ago

TTI's Substantial Addressable Market

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a...
MarketMakerss - November 21, 2024

TTI's Important Core Patent Allowed in Europe

Important Core Patent Allowed In Europe - Thiogenesis Therapeutics (TTI.v) Announced European Approval   Last week...
MarketMakerss - November 11, 2024

RE:RE:RE:RE:listing today

H1..
Bassenon123 - April 22, 2022

RE:RE:RE:listing today

Complete in H1 or Q1?
GoodAtCharts - April 20, 2022

RE:RE:listing today

Waiting to hear the results of the PK study in Australia (dosage in 12 volunteers) which is expected to complete in H1 2022
Bassenon123 - April 20, 2022
View more Bullboard ››

GameSquare Holdings Inc.

GameSquare Holdings Inc.

GameSquare Holdings, Inc. is a vertically integrated, digital media, entertainment and technology company. It connects global ...
View More »